Target intelligence / Profile preview

Bridge-like lipid transfer protein family member 1 (BLTP1)

Target
BLTP1
Molecular classification
Lipid transfer protein, Tube-forming protein, Other
01

Overview

Bridge-like lipid transfer protein family member 1 (BLTP1) is a large, tube-forming lipid transfer protein found in eukaryotes, including humans, where it is encoded by the KIAA1109 gene. BLTP1 mediates non-vesicular phospholipid transport at membrane contact sites, especially trafficking lipids from the endoplasmic reticulum to other organelles or the plasma membrane. Its hydrophobic repeating β-groove (RBG) domains enable bulk transfer of lipids, supporting membrane expansion, cell signaling, and adaptation to physiological stress. It plays essential roles in development, lipid homeostasis, and pathways related to cilia structure, endosomal recycling, and phagocytosis. Pathogenic variants in BLTP1 cause Alkuraya-Kucinskas syndrome, a severe neurodevelopmental disorder, and are implicated in other conditions affecting epithelial growth and tumorigenesis. There are currently no drugs directly targeting BLTP1, though its biological importance is increasingly recognized, and supplementation with lipid-rich compounds (such as lecithin) can ameliorate phenotypes in certain disease models

Other names
FSAKIAA1109KIAA1371TweekFLJ21404fragile site-associated proteinAlkuraya-Kučinskas syndrome genebridge-like lipid transfer protein family member 1BLTP1
02

Mechanism of action

Not targeted by approved drugs; lecithin (a dietary supplement) has been shown to rescue mutant phenotypes in model organisms, suggesting indirect modulation of BLTP1 function through phospholipid supplementation

03

Biological functions

Non-vesicular lipid transport at membrane contact sitesPhospholipid (including phosphatidylethanolamine) transferGlycosylphosphatidylinositol (GPI) anchor synthesisEndosomal traffickingEndosome recyclingRegulation of actin cytoskeleton and cilia structural dynamicsRegulation of phagocytosis
04

Disease associations

Alkuraya-Kucinskas syndromeRight aortic arch (congenital heart disease)Tumor developmentPossible links to Parkinson's disease
05

Safety considerations

None documented for therapeutic targeting, as there are currently no clinically approved drugs directly targeting BLTP1
06

Biomarkers

Mutations in BLTP1 serve as genetic markers for Alkuraya-Kucinskas syndromeNo established protein or chemical biomarkers for patient selection or monitoring

Beyond the preview

Go deeper on Bridge-like lipid transfer protein family member 1 (BLTP1).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Bridge-like lipid transfer protein family member 1 (BLTP1).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call